CTRI/2013/03/003517已完成未知
Safety and Efficacy of 60% Formic Acid formulation combined with a hydrocolloid patch in the treatment of Corns/ Calluses
nigroupAps0 个研究点目标入组 72 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patient have corn/callus on the feet and give informed consent(patient or guardian)/Assent,age above 8 years, both sexes,patient willing to come for regular follow up.
排除标准
- •Age less than 8years,Patients not willing to come for regular follow up,Patients with uncontrolled diabetes,Patients with uncontrolled systemic diseases, not willing to give informed consent.
研究者
相似试验
进行中（未招募）
不适用
Efficacy and safety of fumaric acid esters in the treatment of patients with cutaneous lupus erythematosus: A monocentre, open-label, prospective pilot study - FumaCLEEUCTR2010-023645-29-DEniversitätsklinikum Münster11
进行中（未招募）
1 期
Safety and efficacy of Orally Administered Fx-1006A in Patients with Familial Amyloid Polyneuropathy (FAP): a Phase II/III, Randomised, Double-Blind, Placebo-Controlled StudyFamilial Amyloid Polyneuropathy (FAP).EUCTR2006-002792-41-GBFoldRx Pharmaceuticals, Inc.120
进行中（未招募）
不适用
Safety and Efficacy of Orally Administered Fx-1006A in Patients with Familial Amyloid Polyneuropathy (FAP): a Phase II/III, Randomised, Double-Blind, Placebo-Controlled StudyFamilial Amyloid Polyneuropathy (FAP).MedDRA version: 9.1Level: LLTClassification code 10057949Term: Familial amyloid polyneuropathyEUCTR2006-002792-41-SEFoldRx Pharmaceuticals Limited120
进行中（未招募）
不适用
Safety and Efficacy of Orally Administered Fx-1006A in Patients with Familial Amyloid Polyneuropathy (FAP): A Phase II/III, Randomised, Double-Blind, Placebo-Controlled Study - Not applicableFamilial Amyloid Polyneuropathy (FAP)MedDRA version: 9.1Level: LLTClassification code 10057949Term: Familial amyloid polyneuropathyEUCTR2006-002792-41-DEFoldRx Pharmaceuticals Limited120
进行中（未招募）
不适用
Safety and Efficacy of Orally Administered Fx-1006A in Patients with Familial Amyloid Polyneuropathy (FAP): a Phase II/III, Randomised, Double-Blind, Placebo-Controlled StudyEUCTR2006-002792-41-PTFoldRx Pharmaceuticals, Inc.120